Armata Pharmaceuticals, Inc. ARMP
3.74
0.12
3.31%
as of 25 Sep
- Market cap
- $136.5M
- P/E
- 0.0×
Follow ARMP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 127.83% | 154.70% | 130.37% | 64.00% |
+8 more TTM periods Free account |
|
| (225.11%) | (359.90%) | (212.83%) | (49.96%) | ||
ROIC |
(89.61%) | (87.61%) | (77.26%) | (57.94%) | |
Return on Tangible Assets |
90.73% | (3,325.65%) | (1,249.00%) | 42.46% | |
Average Days of Receivables |
166.73 | 3.30 | 35.13 | 54.82 | |
Free Cash Flow per Share |
(0.70) | (0.67) | (0.73) | (0.76) | |
Free Cash Flow |
(25.79) | (24.47) | (26.30) | (27.43) | |
Capital Expenditures |
(0.37) | (0.51) | (0.54) | (0.41) | |
Piotroski F-Score |
2.00 | 3.00 | 2.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(33.32%) | (66.45%) | (54.80%) | (41.25%) | |
Accounts Receivable Turnover |
2.36 | 36.51 | 8.07 | 3.39 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
461.68% | 469.03% | 483.63% | 516.36% | |
Selling, General and Administrative Expense of Revenue |
274.87% | 242.58% | 253.04% | 243.49% | |
Share Based Compensation of Revenue |
103.19% | 55.82% | 53.22% | 46.14% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.13 | 0.08 | 0.15 | 0.58 | |
Depreciation/Fixed assets |
0.16 | 0.14 | 0.13 | 0.12 | |
Capex/Depreciation |
(0.20) | (0.31) | (0.35) | (0.28) | |
Revenue per Share |
0.15 | 0.14 | 0.14 | 0.14 | |
Operating CF per Share |
(0.69) | (0.66) | (0.71) | (0.75) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.07 | 0.10 | 0.11 | 0.08 | |
Net Profit Margin |
(3,467.04%) | (5,432.80%) | (3,544.03%) | (928.00%) |
Columns are period end dates